Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis

What happened: Eli Lilly reported positive one-year Phase 3 SHINE-2 results for Omvoh (mirikizumab-mrkz) in pediatric patients ages 6 to 17 with moderately to severely active ulcerative colitis, meeting the primary endpoint of clinical remission. Why it matters: Omvoh is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric UC, and if approved it would be the first in its class indicated for pediatric UC. The pediatric Week 52 remission rate was similar to adult Week 12 responders in LUCENT-2 (50.7%), a descriptive observation not a direct comparison. Market: +0.4% today ($1,257.03), +16.8% YTD, 1.0x vol — as of 09:30 UTC

Eli Lilly reported positive one-year Phase 3 SHINE-2 results for Omvoh (mirikizumab-mrkz) in pediatric patients ages 6 to 17 with moderately to severely active ulcerative colitis, meeting the primary endpoint of clinical remission.

Omvoh is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric UC, and if approved it would be the first in its class indicated for pediatric UC. The pediatric Week 52 remission rate was similar to adult Week 12 responders in LUCENT-2 (50.7%), a descriptive observation not a direct comparison. Market: +0.4% today ($1,257.03), +16.8% YTD, 1.0x vol — as of 09:30 UTC